Codexis (NASDAQ:CDXS) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Friday.

A number of other analysts have also recently commented on the company. HC Wainwright restated a “buy” rating and issued a $8.50 price objective on shares of Codexis in a research report on Tuesday, November 21st. Jefferies Group boosted their price objective on Codexis from $9.00 to $11.00 and gave the company a “buy” rating in a research report on Friday, October 13th. Zacks Investment Research upgraded Codexis from a “sell” rating to a “hold” rating in a research report on Wednesday, October 11th. Finally, ValuEngine upgraded Codexis from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $7.50.

Codexis (CDXS) traded up $0.15 during trading on Friday, hitting $7.70. The stock had a trading volume of 300,009 shares, compared to its average volume of 233,598. Codexis has a 1-year low of $3.60 and a 1-year high of $7.95.

Large investors have recently modified their holdings of the company. Wells Fargo & Company MN boosted its stake in shares of Codexis by 103.2% in the second quarter. Wells Fargo & Company MN now owns 119,294 shares of the biotechnology company’s stock worth $650,000 after acquiring an additional 60,600 shares during the last quarter. William Blair Investment Management LLC boosted its stake in Codexis by 10.5% during the second quarter. William Blair Investment Management LLC now owns 1,090,072 shares of the biotechnology company’s stock worth $5,941,000 after buying an additional 103,233 shares during the last quarter. Telemark Asset Management LLC acquired a new position in Codexis during the third quarter worth $13,633,000. Baillie Gifford & Co. boosted its stake in Codexis by 1.1% during the third quarter. Baillie Gifford & Co. now owns 1,478,097 shares of the biotechnology company’s stock worth $9,830,000 after buying an additional 16,684 shares during the last quarter. Finally, Northern Trust Corp boosted its stake in Codexis by 28.8% during the second quarter. Northern Trust Corp now owns 453,656 shares of the biotechnology company’s stock worth $2,473,000 after buying an additional 101,432 shares during the last quarter. 65.71% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This piece was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/12/16/codexis-cdxs-upgraded-to-buy-at-bidaskclub.html.

About Codexis

Codexis, Inc is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale.

Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.